Interleukin-6 (IL-6) Inhibitors Market Size Worth $86.31 Billion By 2032 | CAGR: 10.4%

The global interleukin-6 (IL-6) inhibitors market size is expected to reach USD 86.31 billion by 2032, according to a new study by Polaris Market Research. The report “Interleukin-6 (IL-6) Inhibitors Market Share, Size, Trends, Industry Analysis Report, By Drug Type (Tocilizumab, Siltuximab, and Sylvant); By Disease Type; By Distribution Channel; By Region; Segment Forecast, 2023 - 2032” gives a detailed insight into current market dynamics and provides analysis on future market growth.

The growing popularity of interleukin-6 (IL-6) inhibitors has led businesses and many organizations to invest in research and development. For example, in December 2022, Tocilizumab (Actemra), administered intravenously (IV), was authorized by the US Food and Drug Administration (FDA) for the management of COVID-19 in hospitalized individuals receiving extra care. Tocilizumab was the first monoclonal antibody approved by the FDA to treat the pandemic virus, thanks to the approval given to Roche. In addition to this, in September 2021, Hetero received approval from the Drug Controller General of India (DCGI) for the sale of a biosimilar version of Tocilizumab, a Covid-19 medication for hospitalized people. Contributions of several organizations and industry participants are significantly augmenting the market's growth worldwide.

The increasing prevalence of autoimmune and inflammatory diseases will likely spur the global market’s development. IL-6 is critical in the pathogenesis of various autoimmune and inflammatory diseases, such as rheumatoid arthritis, juvenile idiopathic arthritis, Castleman disease, and cytokine release syndrome (CRS). The rising prevalence of these conditions worldwide drives the demand for effective therapies like IL-6 inhibitors.

Do you have any questions? Would you like to request a sample or make an inquiry before purchasing this report? Simply click the link below: https://www.polarismarketresearch.com/industry-analysis/interleukin6-il6-inhibitors-market/request-for-sample

The increasing prevalence of chronic inflammatory conditions is one of the primary factors likely to enhance the market's growth globally. Chronic inflammatory conditions such as rheumatoid arthritis, juvenile idiopathic arthritis, and Castleman disease are rising globally. For example, as per the estimates, 4 to 16 out of every 10,000 kids in North America and Europe will have juvenile idiopathic arthritis. IL-6 inhibitors have shown efficacy in managing the symptoms and progression of these conditions, driving the demand for IL-6 inhibitors. Henceforth, this heightens the development in the global market.

Interleukin-6 (IL-6) Inhibitors Market Report Highlights

• Tocilizumab drug is anticipated to record the largest market share in the year of 2022 as it was one of the first IL-6 inhibitors to receive regulatory approval and enter the market 
• Rheumatoid arthritis disease type is expected to garner the largest revenue in the global market due to relatively high prevalence of the diseases
• Specialty retailers segment is accounting largest market share of the global revenue in the fiscal year of 2022 as these are a key distribution channel for IL-6 inhibitors
• North America held the largest share as of 2022 due to increasing clinical trials among companies and organizations and surging research and development in the industry
• The global players include AbbVie, inc., AstraZeneca, Bausch Health, Johnson and Johnson Services, Novartis, GlaxoSmithKline, Eli Lilly, Teva Pharmaceutical, Regeneron Pharmaceuticals, Roche, and others

Polaris Market Research has segmented the Interleukin-6 (IL-6) Inhibitors market report based on drug type, disease type, and distribution channel, and region:

Interleukin-6 (IL-6) Inhibitors, Type Outlook (Revenue - USD Billion, 2019-2032)

• Tocilizumab
• Siltuximab
• Sylvant

Interleukin-6 (IL-6) Inhibitors, Disease Type Outlook (Revenue - USD Billion, 2019-2032)

• Rheumatoid Arthritis
• Castleman's disease
• Cancers (Renal cancer, Prostate cancer)
• Arteritis

Interleukin-6 (IL-6) Inhibitors, Distribution Channel Outlook (Revenue - USD Billion, 2019-2032)

• Retail Pharmacies
• Hospital pharmacies
• Specialty pharmacies
• Online pharmacies
• Other Sales Channel

Interleukin-6 (IL-6) Inhibitors, Regional Outlook (Revenue - USD Billion, 2019-2032)

• North America

• U.S.
• Canada

• Europe

• Germany
• UK
• France
• Italy
• Spain
• Russia
• Netherlands

• Asia Pacific

• China
• India
• Japan
• South Korea
• Indonesia
• Malaysia

• Latin America

• Argentina
• Brazil
• Mexico

• Middle East & Africa

• UAE
• Saudi Arabia
• Israel
• South Africa

Interleukin-6 (IL-6) Inhibitors Market Report Scope